Atea Pharmaceuticals, Inc. — Q3 2023 Form 10-Q Summary
Business context and reporting period
Atea is a clinical-stage biopharmaceutical company focused on antiviral therapeutics. The report covers the quarter and nine months ended September 30, 2023. The principal programs were Phase 3 SUNRISE-3 evaluating bemnifosbuvir for high-risk, non-hospitalized COVID-19 patients and a Phase 2 trial evaluating bemnifosbuvir plus ruzasvir for hepatitis C. The company has no approved products and has generated no product revenue.
Financial condition and key metrics
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Research and development expense | $28.2 million | $79.2 million |
| General and administrative expense | $12.6 million | $38.4 million |
| Total operating expenses | $40.8 million | $117.6 million |
| Interest income and other, net | $7.9 million | $21.5 million |
| Net loss | $33.1 million | $96.8 million |
| Net loss per share | $0.40 | $1.16 |
| Net cash used in operating activities | Not separately provided | $63.6 million |
There was no revenue and therefore no meaningful revenue-based margin. September 30, 2023 cash and cash equivalents were $137.9 million, and marketable securities were $457.2 million, for total cash, cash equivalents and marketable securities of approximately $595.1 million. Total assets were $608.1 million and stockholders’ equity was $581.7 million.
The filing does not report outstanding debt. Operating lease liabilities totaled $2.6 million, including $0.8 million current and $1.8 million non-current. The company maintained a full valuation allowance against deferred tax assets.
Material changes versus the prior comparable period
- Third-quarter R&D expense increased $23.3 million, or approximately 475%, to $28.2 million, primarily because of higher spending on SUNRISE-3 and the HCV program and lower Roche reimbursement credits.
- Nine-month R&D expense increased $24.8 million, or approximately 46%, to $79.2 million.
- Third-quarter net loss increased $25.1 million to $33.1 million; nine-month net loss increased $15.3 million to $96.8 million.
- Interest income increased by $3.5 million in the quarter and $15.9 million year to date, reflecting higher yields and investment in higher-yielding securities.
- Operating cash use improved to $63.6 million from $99.4 million in the prior-year period, while investing cash flow changed to $12.5 million provided from $488.9 million used, primarily because the company sold or received maturities of marketable securities in 2023.
- Roche-related R&D credits were $3.7 million in the quarter and $12.6 million year to date, compared with $14.6 million and $5.8 million, respectively, in the prior-year periods. These credits relate to close-out activities following Roche’s 2022 license termination.
Guidance, outlook, risks and unusual items
- Management expects available cash, cash equivalents and marketable securities to fund planned operations into 2026, although the company expects operating expenses and cash needs to increase substantially as clinical programs advance.
- SUNRISE-3 was amended to broaden eligibility and increase the supportive-care population to approximately 2,200 patients from an initial target of at least 1,300. The amendment reflects lower-than-expected COVID-19 hospitalization and death rates and includes interim DSMB reviews after approximately 650 and 1,350 patients complete Day 29.
- The lead-in cohort of approximately 60 patients in the Phase 2 HCV study was complete, with preliminary data then expected in the first quarter of 2024. The full study is expected to enroll approximately 280 patients.
- Atea discontinued further development of AT-752 for dengue in February 2023 because of enrollment challenges, operational burdens, long timelines and expected costs. The company also terminated RSV discovery activities to focus resources on more advanced programs.
- The company is exploring discovery or acquisition of a protease inhibitor for potential combination use with bemnifosbuvir in COVID-19; these activities remain at an early stage and may require additional preclinical and clinical work.
- Material risks include clinical-trial failure or delay, changing COVID-19 epidemiology and treatment standards, competition from approved and developing antivirals, dependence on CROs and CMOs, future financing needs, and regulatory approval uncertainty.
- Atea is challenging a Gilead patent claim that purports to cover bemnifosbuvir. An adverse outcome could require a license from Gilead before commercialization, potentially on unfavorable terms or not at all. Two Indian pre-grant patent oppositions remain pending.
- The company had an open-market sales agreement permitting up to $200 million of common-stock sales, but no shares had been issued under the agreement as of September 30, 2023.
- Management concluded that disclosure controls and procedures were effective as of September 30, 2023, with no material changes in internal control over financial reporting.
Important facts for investors to verify
- Progress, enrollment, interim reviews and eventual efficacy and safety results for SUNRISE-3, including the effect of the larger sample size and lower event rates.
- Preliminary and final results from the bemnifosbuvir-plus-ruzasvir HCV program and the timing and requirements for any Phase 3 study.
- Actual cash burn, investment maturities and whether the stated funding runway into 2026 remains valid as development spending increases.
- Status and potential consequences of the Gilead patent challenge and the two Indian patent oppositions.
- Whether bemnifosbuvir can compete with established COVID-19 therapies and whether the evolving commercial and reimbursement environment supports a viable market.
- Future financing requirements and potential dilution, given the company’s continuing losses and lack of product revenue.